Literature DB >> 31721989

Age-Specific Incidence of Melanoma in the United States.

Kelly G Paulson1,2,3, Deepti Gupta4,5,6, Teresa S Kim3,7, Joshua R Veatch1,2,3, David R Byrd3,7, Shailender Bhatia1,2,3, Katherine Wojcik1, Aude G Chapuis1,2,3, John A Thompson1,2,3, Margaret M Madeleine8,9, Jennifer M Gardner3,5.   

Abstract

Importance: Melanoma is epidemiologically linked to UV exposure, particularly childhood sunburn. Public health campaigns are increasing sun-protective behavior in the United States, but the effect on melanoma incidence is unknown. Objective: To examine the incidence of melanoma in the United States and whether any age-specific differences are present. Design, Setting, and Participants: Observational, population-based registry data were extracted on July 3, 2018, from the combined National Program of Cancer Registries-Surveillance Epidemiology and End Results United States Cancer Statistics database for 2001-2015. Deidentified data for 988 103 cases of invasive melanoma, with International Classification of Diseases for Oncology histologic categorization codes 8720 to 8790, were used for analysis. Data analysis was performed from July 1, 2018, to March 1, 2019. Main Outcomes and Measures: The annual rates of melanoma in pediatric, adolescent, young adult, and adult age groups were determined. Analyses were stratified by sex, and incidence rates were age-adjusted to the 2000 US standard population. Annual percentage change (APC) in incidence rate was calculated over the most recent decade for which data were available (2006-2015) using the weighted least squares method.
Results: In 2015, 83 362 cases of invasive melanoma were reported in the United States, including 67 in children younger than 10 years, 251 in adolescents (10-19 years), and 1973 in young adults (20-29 years). Between 2006 and 2015, the overall incidence rate increased from 200.1 to 229.1 cases per million person-years. In adults aged 40 years or older, melanoma rates increased by an APC of 1.8% in both men (95% CI, 1.4%-2.1%) and women (95% CI, 1.4%-2.2%). In contrast, clinically and statistically significant decreases were seen in melanoma incidence for adolescents and young adults. Specifically, incidence rates decreased by an APC of -4.4% for male adolescents (95% CI, -1.7% to -7.0%), -5.4% for female adolescents (95% CI, -3.3% to -7.4%), -3.7% for male young adults (95% CI, -2.5% to -4.8%), and -3.6% for female young adults (95% CI, -2.8% to -4.5%). Data on skin pigmentation and sun protection history were unavailable; similar trends were observed with data limited to non-Hispanic whites. Young adult women appeared to have twice the risk of melanoma as young adult men. Conclusions and Relevance: The incidence of invasive melanoma in the United States appeared to decrease in adolescents and young adults from 2006 to 2015, and this finding contrasted with increases in older populations. These incidence trends suggest that public health efforts may be favorably influencing melanoma incidence in the United States.

Entities:  

Mesh:

Year:  2020        PMID: 31721989      PMCID: PMC6865303          DOI: 10.1001/jamadermatol.2019.3353

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  35 in total

Review 1.  The pathogenesis of melanoma induced by ultraviolet radiation.

Authors:  B A Gilchrest; M S Eller; A C Geller; M Yaar
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Linda Rollin; James Larkin
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

3.  Melanoma Incidence in Children and Adolescents: Decreasing Trends in the United States.

Authors:  Laura B Campbell; Kathryn L Kreicher; Haley R Gittleman; Kyle Strodtbeck; Jill Barnholtz-Sloan; Jeremy S Bordeaux
Journal:  J Pediatr       Date:  2015-04-09       Impact factor: 4.406

4.  Reduced melanoma after regular sunscreen use: randomized trial follow-up.

Authors:  Adèle C Green; Gail M Williams; Valerie Logan; Geoffrey M Strutton
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

5.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

Authors:  Sandra P D'Angelo; James Larkin; Jeffrey A Sosman; Celeste Lebbé; Benjamin Brady; Bart Neyns; Henrik Schmidt; Jessica C Hassel; F Stephen Hodi; Paul Lorigan; Kerry J Savage; Wilson H Miller; Peter Mohr; Ivan Marquez-Rodas; Julie Charles; Martin Kaatz; Mario Sznol; Jeffrey S Weber; Alexander N Shoushtari; Mary Ruisi; Joel Jiang; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

6.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

7.  Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children.

Authors:  Kelly M Cordoro; Deepti Gupta; Ilona J Frieden; Timothy McCalmont; Mohammed Kashani-Sabet
Journal:  J Am Acad Dermatol       Date:  2013-02-08       Impact factor: 11.527

8.  Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis.

Authors:  Leslie K Dennis; Marta J Vanbeek; Laura E Beane Freeman; Brian J Smith; Deborah V Dawson; Julie A Coughlin
Journal:  Ann Epidemiol       Date:  2008-08       Impact factor: 3.797

9.  High Birth Weight, Early UV Exposure, and Melanoma Risk in Children, Adolescents, and Young Adults.

Authors:  Katherine Y Wojcik; Loraine A Escobedo; Ashley Wysong; Julia E Heck; Beate Ritz; Ann S Hamilton; Joel Milam; Myles G Cockburn
Journal:  Epidemiology       Date:  2019-03       Impact factor: 4.860

10.  The age of enlightenment in melanoma immunotherapy.

Authors:  Mark R Albertini
Journal:  J Immunother Cancer       Date:  2018-08-22       Impact factor: 13.751

View more
  35 in total

1.  Increased Uniformity in Diagnostic Accuracy of Pigmented Lesions Using Electrical Impedance Spectroscopy Information.

Authors:  Graham Litchman; Rebeca Teplitz; Ryan M Svoboda; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2021-10

2.  Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma.

Authors:  Richard J Straker; Jerica C Tidwell; Cimarron E Sharon; Emily Y Chu; John T Miura; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2022-03-16       Impact factor: 5.344

Review 3.  Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers.

Authors:  Dimitrios C Ziogas; Anastasios Martinos; Dioni-Pinelopi Petsiou; Amalia Anastasopoulou; Helen Gogas
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

4.  Landmark Series on Disparities in Surgical Oncology: Melanoma.

Authors:  Elliot A Asare; Umang Swami; John H Stewart
Journal:  Ann Surg Oncol       Date:  2021-06-30       Impact factor: 5.344

5.  The ionophore thiomaltol induces rapid lysosomal accumulation of copper and apoptosis in melanoma.

Authors:  Ottis Scrivner; Long Dao; M Karen Newell-Rogers; Babbak Shahandeh; Frank L Meyskens; Susan Kurumi Kozawa; Feng Liu-Smith; Germán Plascencia-Villa; Miguel José-Yacamán; Shang Jia; Christopher J Chang; Patrick J Farmer
Journal:  Metallomics       Date:  2022-01-17       Impact factor: 4.526

6.  Environmental effects of stratospheric ozone depletion, UV radiation, and interactions with climate change: UNEP Environmental Effects Assessment Panel, Update 2020.

Authors:  R E Neale; P W Barnes; T M Robson; P J Neale; C E Williamson; R G Zepp; S R Wilson; S Madronich; A L Andrady; A M Heikkilä; G H Bernhard; A F Bais; P J Aucamp; A T Banaszak; J F Bornman; L S Bruckman; S N Byrne; B Foereid; D-P Häder; L M Hollestein; W-C Hou; S Hylander; M A K Jansen; A R Klekociuk; J B Liley; J Longstreth; R M Lucas; J Martinez-Abaigar; K McNeill; C M Olsen; K K Pandey; L E Rhodes; S A Robinson; K C Rose; T Schikowski; K R Solomon; B Sulzberger; J E Ukpebor; Q-W Wang; S-Å Wängberg; C C White; S Yazar; A R Young; P J Young; L Zhu; M Zhu
Journal:  Photochem Photobiol Sci       Date:  2021-01-20       Impact factor: 4.328

Review 7.  Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs.

Authors:  Alessandra Buja; Massimo Rugge; Giovanni Damiani; Manuel Zorzi; Chiara De Toni; Antonella Vecchiato; Paolo Del Fiore; Romina Spina; Vincenzo Baldo; Alessandra Rosalba Brazzale; Carlo Riccardo Rossi; Simone Mocellin
Journal:  J Womens Health (Larchmt)       Date:  2022-01-25       Impact factor: 3.017

Review 8.  The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.

Authors:  Asurayya Worrede; Stephen M Douglass; Ashani T Weeraratna
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

9.  Incidence of Cutaneous Melanoma of Eyelid Analysis of the Surveillance, Epidemiology, and End Results Database.

Authors:  Philip Brunetti; Curtis E Margo; Dustin D French
Journal:  Ocul Oncol Pathol       Date:  2020-11-17

10.  Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Authors:  E E A P Mulder; J T Dwarkasing; D Tempel; A van der Spek; L Bosman; D Verver; A L Mooyaart; A A M van der Veldt; C Verhoef; T E C Nijsten; D J Grunhagen; L M Hollestein
Journal:  Br J Dermatol       Date:  2020-11-02       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.